Janssen submits application to EMA for mantle cell lymphoma therapy approval
The company sought approval for the combination therapy to treat previously untreated mantle cell lymphoma (MCL) adult patients not suitable for autologous stem cell transplantation (ASCT). Jointly developed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.